GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Minority Interest

Alto Neuroscience (Alto Neuroscience) Minority Interest : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Alto Neuroscience's minority interest for the quarter that ended in Mar. 2024 was $0.00 Mil.

Alto Neuroscience Minority Interest Historical Data

The historical data trend for Alto Neuroscience's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Minority Interest Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Minority Interest
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Minority Interest Get a 7-Day Free Trial - - - - -

Alto Neuroscience Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Minority Interest
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024